Laying the foundations for personalized medicines

Nature Biotechnology

Volumn 15, Issue 10, 1997, Pages 954-957

  Marshall, Andrew ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME ACTIVITY; GENETIC VARIABILITY; HUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW;

CLINICAL TRIALS, PHASE III; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; ISOENZYMES; MOLECULAR BIOLOGY; MUTATION; PEDIGREE; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOKINETICS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 0030770412     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1097-954     Document Type: Article

References (6)

1. Motulsky, A. 1957, Drug reactions, enzymes, and biochemical genetics. J. Am. Med. Assoc. 165:835-837.
2. Kalow, W. 1962. Pharmacogenetics—Heredity and the Responses to Drugs. W.B. Saunders, Philadelphia.
3. Vessell, E.S., Page, J.G., and Passanti, T.G. 1971. Genetic and environmental factors affecting ethanol metabolism. Clin. Pharmacol. Ther. 12:192-201.
4. Weber, W.W. 1997. Pharmacogenetics. Oxford University Press, New York.
5. Lichter, J. and McNamara, D. 1995. What’s in a gene: using genetic information for the design of clinical trials. Curr. Opin. Biotechnol. 6:715-717.
6. Meyer, U.A. 1997. Medically relevant genetic variation of drug effects. Evolution in Health and Disease. Oxford University Press, Oxford, UK. In press.